Deconvoluting the obesity and breast cancer link: Secretome, soil and seed interactions

Journal of Mammary Gland Biology and Neoplasia

Volumn 18, Issue 3-4, 2013, Pages 267-275

  Ford, Nikki A ^a   Devlin, Kaylyn L ^b   Lashinger, Laura M ^a   Hursting, Stephen D ^a,c,d  

^a University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Breast cancer; Inflammation; Insulin; Leptin; Obesity; p53

Indexed keywords

ADIPONECTIN; CHEMOKINE; CYANOCOBALAMIN; CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; GLUCOCORTICOID; GROWTH FACTOR; INSULIN; INTERLEUKIN 6; INTRINSIC FACTOR; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 16; MICRORNA 200C; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SCATTER FACTOR; SOMATOMEDIN C; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADIPOCYTE; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BROWN ADIPOSE TISSUE; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENERGY BALANCE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; MACROPHAGE; MAST CELL; METASTASIS; NONHUMAN; OBESITY; POSTMENOPAUSE; T LYMPHOCYTE; TISSUE DIFFERENTIATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; OBESITY; PROTEOME; RISK FACTORS; SECRETORY PATHWAY; TUMOR MICROENVIRONMENT;

EID: 84890092546     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-013-9301-9     Document Type: Article

References (101)

1. Finucane MM et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557-67.
2. Flegal KM et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-7.
3. Prevention, C.f.D.C.a. 2012; Available from: http://www.cdc.gov/nchs/ fastats/bodymeas.htm.
4. Available from: http://www.iaso.org/resources/obesity-data-portal/ resources/charts/.
5. Reeves GK et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.
6. Yang XR et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-63.
7. Prat A et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res: BCR. 2010;12(5):R68.
8. Dogan S et al. Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. Breast Cancer Res. 2007;9(6):R91.
9. Dunlap SM et al. Dietary energy balance modulates epithelial-to- mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res. 2012;5(7):930-42.
10. Giles ED et al. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 2012;72(24):6490-501.
11. Hakkak R et al. Obesity increases the incidence of 7,12-dimethylbenz(a) anthracene-induced mammary tumors in an ovariectomized Zucker rat model. Int J Oncol. 2007;30(3):557-63.
12. Cleary MP et al. Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer. 2004;50(2):174-80.
13. Ford NA et al. IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression. Endocr-Relat Cancer. 2013;20(1):39-51.
14. Mizuno NK et al. Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. Cancer Prev Res. 2013;6(6):540-7.
15. Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol. 2012;32(8):1766-70.
16. Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteome. 2010;73(12):2291-305.
17. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-3.
18. Brown KJ et al., The human secretome atlas initiative: Implications in health and disease conditions. Biochimica et Biophysica Acta, 2013.
19. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13(6):227.
20. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:E1-19.
21. Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1-2):69-78.
22. Nam SY et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 1997;21(5):355-9.
23. Hursting SD et al., Calories and cancer: the role of insulin-like growth factor-1, in The IGF system and cancer, D. Leroith, Editor 2011, Springer, NY. p. 231-243.
24. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-28.
25. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20(1):87-90.
26. Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009;21(5):656-64.
27. Moore T et al. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila). 2008;1(1):65-76.
28. De Angel RE et al. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog. 2013;52(6):446-58.
29. Nogueira LM et al. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer. 2012;19(1):57-68.
30. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest. 2011;121(6):2087-93.
31. Gross A et al., Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev, 2013.
32. Wu MH et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009;100(4):578-82.
33. Mantzoros CS et al. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer. 1999;80(4):523-6.
34. Petridou E et al. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control. 2000;11(5):383-8.
35. Stattin P et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat. 2004;86(3):191-6.
36. Harris HR et al. Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res (Phila). 2011;4(9):1449-56.
37. Cirillo D et al. Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008;105(4):956-64.
38. Vaiopoulos AG et al. The role of adiponectin in human vascular physiology. Int J Cardiol. 2012;155(2):188-93.
39. Miyoshi Y et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9(15):5699-704.
40. Mantzoros C et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89(3):1102-7.
41. Tian YF et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer. 2007;14(3):669-77.
42. Tworoger SS et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510-6.
43. Barb D et al. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(3):s858-66.
44. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43(4):157-68.
45. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114(1):71-83.
46. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431-6.
47. Del Prete A et al. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb). 2011;21(3):264-75.
48. Chen DC et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237(1):109-14.
49. Ashizawa N et al. Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol. 2010;119(1):65-9.
50. Cleary MP et al. Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed). 2009;1:329-57.
51. Key TJ et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218-26.
52. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270-82.
53. Pequeux C et al. Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis. Cancer Res. 2012;72(12):3010-9.
54. Brodie AM, Marsh D, Brodie HJ. Aromatase inhibitors-IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17- dione. J Steroid Biochem. 1979;10(4):423-9.
55. Basu S et al. Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations. Antioxid Redox Signal. 2013;18(3):323-60.
56. Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci. 2011;1229:45-52.
57. Subbaramaiah K et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila). 2011;4(3):329-46.
58. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-46.
59. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008;99(8):1501-6.
60. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009;9(4):351-69.
61. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659(1-2):15-30.
62. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
63. Charriere G et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278(11):9850-5.
64. Allavena P et al. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1-9.
65. Calabro P, Yeh ET. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem. 2007;42:63-91.
66. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540-50.
67. Kulbe H et al. The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol. 2004;48(5-6):489-96.
68. Allavena P et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155-61.
69. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007;117(9):2362-8.
70. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777-94.
71. Liu Y et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat. 2011;129(1):175-84.
72. Chen CT et al. Targeting the IKKbeta/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther. 2012;11(10):2212-21.
73. Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol. 2012;157(3):291-8.
74. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res. 2009;2009:345320.
75. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004;28(11):1357-64.
76. Muldowney III JA et al. Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study. Angiology. 2012;63(6):429-34.
77. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
78. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
79. Hollstein M et al. p53 mutations in human cancers. Science. 1991;253(5015):49-53.
80. Molchadsky A et al. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. Cell Death Differ. 2013;20(5):774-83.
81. Park H et al. A high-fat diet increases angiogenesis, solid tumor growth, and lung metastasis of CT26 colon cancer cells in obesity-resistant BALB/c mice. Mol Carcinog. 2012;51(11):869-80.
82. Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol. 2007;21(12):2907-18.
83. Liu G, Schwartz JA, Brooks SC. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res. 2000;60(7):1810-4.
84. Hurd C et al. Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. Oncogene. 1999;18(4):1067-72.
85. Konduri SD et al. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci U S A. 2010;107(34):15081-6.
86. Shirley SH et al. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res. 2009;69(8):3405-14.
87. Zhang X et al. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene. 2005;24(26):4220-31.
88. Fuchs-Young R et al. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat. 2011;130(2):399-408.
89. Freeman EW et al. Obesity and reproductive hormone levels in the transition to menopause. Menopause. 2010;17(4):718-26.
90. Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
91. Skliris GP et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol. 2003;201(2):213-20.
92. Luo J et al. A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J. 2010;10(4):278-91.
93. Wang ZV et al. Identification and characterization of a promoter cassette conferring adipocyte-specific gene expression. Endocrinology. 2010;151(6):2933-9.
94. Karastergiou K et al. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30(7):1340-6.
95. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature. 2009;458(7239):725-31.
96. Elkabets M et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha Inhibitors in PIK3CA-mutant breast cancer. Sci Trans Med. 2013;5(196):196ra99.
97. Njiaju UO, Olopade OI. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012;18(5):436-42.
98. Ford NA et al. Obesity, independent of p53 gene dosage, promotes mammary tumor progression and upregulates the p53 regulator MicroRNA-504. PLoS One. 2013;8(6):e68089.
99. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010-2.
100. Velasco-Velazquez MA et al. Breast cancer stem cells. Int J Biochem Cell Biol. 2012;44(4):573-7.
101. Zheng Q et al. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011;18(4):491-503.